Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Next Previous
Trial Profile

An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imetelstat (Primary) ; Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms IMproveMF
  • Sponsors Geron Corporation

Most Recent Events

  • 28 May 2025 According to Geron Corporation media release, company announced presentation of data from this study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2025 Congress.
  • 18 May 2025 Planned number of patients changed from 41 to 51.
  • 18 May 2025 Planned End Date changed from 1 Aug 2027 to 1 Aug 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top